Medication adherence in people with Parkinson's disease Nervous System Diseases Parkinson's disease
Conditions
Interventions
CAAT-PARK is a brief cognitive-behavioural approach aimed at facilitating a process of shared decision making. CAAT-PARK is rooted in the observation that a person?s beliefs impact on treatment adhere
Sponsors
University of East Angia (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 20/12/2011 1. Adults diagnosed with, or with probable, Idiopathic PD (three out of four of the chief UK Brain Bank criteria) 2. Prescribed one or more anti-parkinsonian medications by a Consultant Neurologist or Consultant Physician with specialist knowledge of movement disorders 3. English speaking and literate (participants are required to actively engage in the therapy process) 4. Stable medication regime i.e. not altered within the previous month, and not expected to change during the period of the research project (12 weeks) 5. Not demented or significantly cognitively impaired as assessed either informally by the clinical team or formally using the Mini-Mental State Examination (MMSE) score of = 24 (recent clinic score used where available) 6. Show poor adherence as determined by a Morisky Medication Adherence Scale (MMAS-4) score of 1 or above Previous inclusion criteria 1. Adults diagnosed with, or with probable, Idiopathic PD (three out of four of the chief UK Brain Bank criteria) 2. Prescribed one or more anti-parkinsonian medications by a Consultant Neurologist or Consultant Physician with specialist knowledge of movement disorders 3. English speaking and literate (participants are required to actively engage in the therapy process) 4. Stable medication regime i.e. not altered within the previous month, and not expected to change during the period of the research project (12 weeks) 5. Not demented or significantly cognitively impaired as assessed either informally by the clinical team or formally using the Mini-Mental State Examination (MMSE) score of = 24 (recent clinic score used where available) 6. Show poor adherence as determined by a Morisky Medication Adherence Scale (MMAS-4) score = 2
Exclusion criteria
Exclusion criteria: 1. Suspected Parkinsonism due to other causes than idiopathic PD 2. Treated with anti-parkinsonian medications for a mental health complaint 3. Diagnosed with dementia 4. Life expectancy < 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in adherence to medication determined by the Morisky Medication Adherence Scale (MMAS-4) 2. Change in quality of life (QoL) determined by the Parkinson?s Disease Questionnaire-39 (PDQ-39) | — |
Secondary
| Measure | Time frame |
|---|---|
| People with PD: 1. Movement Disorder Society Unified Parkinson?s Disease Rating Scale (MDS-UPDRS) Part I (non-motor experiences of daily living), Part II (motor experiences of daily living) and Part IV (motor complications) 2. Beliefs about Medication Questionnaire (BMQ) 3. EuroQol quality of life questionnaire (EQ-5D) Spouse/Carer Outcomes: 1. Carer Distress Scale (CDS) 2. BMQ | — |
Countries
United Kingdom
Outcome results
None listed